创新医疗：连续三日股价涨幅偏离值超20%，提示交易风险

Core Viewpoint - The company's stock experienced an abnormal fluctuation with a cumulative closing price increase exceeding 20% over three consecutive trading days in January 2026, despite no significant changes in its operations or external environment [1] Group 1: Stock Performance - The stock price deviation occurred on January 8, 9, and 12, 2026, indicating unusual market activity [1] - The company confirmed that there were no corrections or supplementary disclosures to previously released information [1] Group 2: Business Operations - The company noted high market interest in its brain-computer interface business [1] - The subsidiary, Boling, launched the Cyberlink AC5 product in October 2025, generating revenue of 114,000 yuan in 2025 [1] - The Cyberlink AM5 product did not generate any revenue, and Boling is expected to incur operating losses in 2023 and 2024 [1] Group 3: Investor Advisory - The company advised investors to make rational investment decisions in light of the stock's volatility and the current business performance [1]